The combination of an angiotensin II type 1 receptor blocker (valsartan) and a thiazide diuretic (hydrochlorothiazide) has been evaluated in the treatment of patients with hypertension in several clinical trials. The valsartan/hydrochlorothiazide (VAL-HCT) combination was found to be generally more effective than either drug given alone. The incidence of adverse events in VAL-HCT recipients was...

A stability-indicating HPLC assay method has been developed and validated for valsartan in bulk drug and pharmaceutical dosage forms. An isocratic RP-HPLC was achieved on Waters 2695 using Symmetry C18 (250mm × 4.6mm × 5μ) column with the mobile phase consisting of 0.02 mM sodium dihydrogen ortho-phosphate, pH adjusted to 2.5 using ortho-phosphoric acid (solvent A), and acetonitrile (solvent B)...

BACKGROUND LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin. We aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood pressure, compared with the angiotensin-receptor blocker valsartan. METHODS 1328 patients aged 18-75 years with mild-to-moderate hypertension were randomly assigned (double-blind) to 8 weeks' treatment in one ...

Angiotensin (Ang) II exerts direct effects on the arterial wall to influence atherosclerosis and aneurysm development with the induction of vascular inflammation. Therefore, we examined the hypothesis that the inhibition of Ang II would decrease the expansion of abdominal aortic aneurysm (AAA) in a rat model. We used the Ang II receptor blocker (ARB) valsartan to inhibit the effect of Ang II. A...

Abstract Funding Acknowledgements Type of funding sources: None. Background Heart failure with preserved ejection fraction (HFpEF) is associated frequent hospitalizations and an increased risk death. Empagliflozin was recently reported to reduce the combined cardiovascular death or hospitalization for heart (HF) among patients HFpEF, whereas Sacubitril/Valsartan has shown only marginal signific...

Abstract Background and Aims Sacubitril/valsartan (SV) plays a key role in improving left ventricular remodeling prognosis patients with heart failure. However its effects on kidney function people moderate to severe chronic disease (CKD3b-5) are unknown. The present study was designed assess the efficacy safety of sacubitril-valsartan stage 3b-5 CKD hypertension. Method In this randomized, dou...

BACKGROUND In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pressure reductions were significantly more pronounced with amlodipine. Stroke incidence was non-significantly, and myocardial i...

A spectrophotometric method was developed for simultaneous determination of amlodipine (Aml) and valsartan (Val) without previous separation. In this method amlodipine in methanolic solution was determined using zero order UV spectrophotometry by measuring its absorbency at 360.5 nm without any interference from valsartan.Valsartan spectrum in zero order is totally overlapped with that of amlod...

Beta-blockers, angiotensin-converting–enzyme (ACE) inhibitors, and aldosterone antagonists have been shown to reduce the overall risk of death as well as the risk of major nonfatal cardiovascular events when they are administered to patients with acute myocardial infarction who also have left ventricular systolic dysfunction, clinical evidence of heart failure, or both. 1,2 However, there remai...

A simple, reproducible and efficient reverse phase high performance liquid chromatographic method was developed for simultaneous determination of valsartan and hydrochlorothiazide in tablets. A column having 200 x 4.6 mm i.d. in isocratic mode with mobile phase containing methanol:acetonitrile:water:isopropylalcohol (22:18:68:2; adjusted to pH 8.0 using triethylamine; v/v) was used. The flow ra...